In this article, we describe a pharmacogenetics approach that enables to selectively and reversibly inactivate LC neurons working with Designer Receptors Exclusively Activated by Designer Medications (DREADD). We clearly show that the expression in the hM4Di DREADD might be limited to noradrenergic LC neurons Which the amount of LC inhibition could